A secondary analysis presented at the American Stroke Association’s International Stroke Conference 2020 confirmed the safety of apixaban treatment.
The approvals were granted to generic apixaban applications from Micro Labs Limited and Mylan Pharmaceuticals Inc.
Low-risk atrial fibrillation patients who take oral anticoagulants have a lower risk of dementia than those who do not, a study says.
The use of direct‐acting oral anticoagulants has increased among nursing home residents with atrial fibrillation.
Overestimating the bleeding risk of anticoagulants may lead to poor compliance.
Bleeding in patients with nonvalvular atrial fibrillation and coronary syndrome was reduced by apixaban versus vitamin K antagonists.
Many kidney disease patients with atrial fibrillation are not treated with anticoagulation, increasing their risk of stroke.
Study finds different anticoagulation treatment levels for patients with cognitive problems.
DOACs are as good as warfarin in preventing atrial fibrillation complications.
Three cardiology groups now recommend using NOACs over warfarin in atrial fibrillation.